How to Treat Chronic Myeloid Leukemia (CML) - Dr. Jorge Cortes

Practical Perspectives: Current Management of Chronic Myeloid LeukemiaПодробнее

Jorge Cortes, MD, Shares Data on Asciminib Versus TKIs in CMLПодробнее

Key emerging trials in CML and the importance of improving treatment-free remission ratesПодробнее

5-year update of BFORE: bosutinib vs imatinib in CMLПодробнее

Jorge Cortes, MD, on the Evolution of CML Treatment, Remaining ChallengesПодробнее

Exciting updates in the field of CML: disease pathophysiology & novel agentsПодробнее

Advancements in CML: improving treatment-free remission and novel agentsПодробнее

Practical Perspectives: Current Management of Chronic Myeloid Leukemia — Jorge Cortes, MDПодробнее

Updates in CML Management – Dr. Jorge Cortes (May 26-27, 2023)Подробнее

Dr. Cortes Discusses Approval of Ponatinib for Adults with Chronic-phase CMLПодробнее

Jorge Cortes, MD, discusses the take home message from the OPTIC study in CML patients for HCPsПодробнее

13 Is combination therapy ready for prime time in CML? Prof. Jorge CortesПодробнее

Jorge Cortes, MD, provides thoughts on what the impact of the OPTIC study will be on CML patientsПодробнее

Working towards a cure in CMLПодробнее

Jorge Cortes, MD, tells us about the OPTIC study, a phase 2 investigation of ponatinib in CMLПодробнее

FDA Approves New Dosing for Ponatinib to Treat Chronic Myeloid LeukemiaПодробнее

Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterizationПодробнее

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutationПодробнее

Jorge Cortes, MD, on the evolution of CAR-T cell therapies in hematologic malignancies managementПодробнее